Autoimmune Encephalitis
52
15
18
16
Key Insights
Highlights
Success Rate
94% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
1.9%
1 terminated out of 52 trials
94.1%
+7.6% vs benchmark
4%
2 trials in Phase 3/4
6%
1 of 16 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 16 completed trials
Clinical Trials (52)
A Study in Participants With Anti-NMDAR Encephalitis and Anti-NMDAR Autoantibody-Associated Psychiatric Disease
Phase 1 Study of ART5803 in Healthy Participants
Phase 1 Study of ART5803 Safety and PK After IVIG in Healthy Participants
FDG-PET in the Diagnosis of Autoimmune Encephalitis
Study of Pathogenic Mechanisms and Identification of Novel Autoantibodies in Autoimmune Encephalitis
Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research
Tongji NADs Cohort
A Study of C-CAR168 in the Treatment of Central Nervous System Autoimmune Diseases Refractory to Standard Therapy
Long-term Impact of NMDAR Encephalitis
Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/B Cell Maturation Antigen （CD19/BCMA） in Patients With r/r Neurological Autoimmune Diseases
Monitoring of Outcomes of Cellular and Exosome-based Therapies in Autoinflammatory and Post-infectious Neuroinflammatory Syndromes
Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis
A Prospective Study to Evaluate Clinical Outcomes in Anti-LGI1 Encephalitis
Impact of Confirmed Autoimmune Encephalitis on Brain Glucose Metabolism
hUC-MSC-Exo Therapy for Autoimmune Encephalitis
Efficacy and Safety of Adjunctive Minocycline in the Treatment of Autoimmune Encephalitis
The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis
CPI Combination Therapy for Autoimmune Encephalitis
Clinical Characteristics of Patients With Anti-Collapsin Response Mediator Protein 2 Antibodies in Encephalitis or Encephalomyelitis
Efficacy and Safety of Calculus Bovis Sativus (CBS) for Adult Encephalitis (CBSinEncephalitis)